Brokers Set Expectations for AUTL FY2028 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Equities researchers at William Blair issued their FY2028 earnings estimates for shares of Autolus Therapeutics in a research report issued on Thursday, March 20th. William Blair analyst M. Phipps expects that the company will post earnings per share of ($0.18) for the year. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.94) per share.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to analysts' expectations of $2.98 million.

AUTL has been the topic of several other reports. Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $9.52.

Remove Ads

Autolus Therapeutics Stock Up 1.2 %

Shares of NASDAQ AUTL traded up $0.02 during trading on Monday, reaching $1.65. 643,466 shares of the company traded hands, compared to its average volume of 1,379,402. The stock has a market capitalization of $439.06 million, a PE ratio of -1.36 and a beta of 2.07. The firm has a 50 day simple moving average of $1.98 and a 200-day simple moving average of $2.86. Autolus Therapeutics has a 52-week low of $1.56 and a 52-week high of $6.44.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in shares of Autolus Therapeutics by 4.6% in the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock valued at $59,562,000 after purchasing an additional 1,125,454 shares during the period. FMR LLC increased its stake in Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after purchasing an additional 5,478,706 shares during the period. TFG Asset Management GP Ltd grew its stake in Autolus Therapeutics by 3.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company's stock worth $19,388,000 after purchasing an additional 250,000 shares in the last quarter. Candriam S.C.A. acquired a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $7,500,000. Finally, AXA S.A. acquired a new stake in shares of Autolus Therapeutics in the 4th quarter valued at $4,288,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.